ADC Therapeutics (ADCT) Debt Ratio (2020 - 2026)

ADC Therapeutics (ADCT) posted Debt Ratio of 0.4 for Q1 2026, up 11.08% sequentially from 0.36 in Q4 2025, and down 4.98% YoY from 0.42 in Q1 2025.

ADC Therapeutics (ADCT) Debt Ratio (2020 - 2026) Analysis & Trends

ADC Therapeutics has reported Debt Ratio for 7 years, with the latest figure at 0.4 in Q1 2026.

Quarterly Debt Ratio fell 4.98% year-over-year to 0.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.4 (down 4.98% YoY) and the FY2025 annual result came in at 0.36, up 1.23% from the prior year.
Debt Ratio rose to 0.4 in Q1 2026 per ADCT's latest filing, from 0.36 in the prior quarter.
Over five years, Debt Ratio peaked at 0.42 in Q1 2025 and troughed at 0.16 in Q1 2022.
A 5-year average of 0.3 and a median of 0.32 in 2023 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 91.41% in 2022, down 5.3% in 2022.
Over 5 years, Debt Ratio stood at 0.25 in 2022, then gained by 27.65% to 0.32 in 2023, then rose by 11.07% to 0.35 in 2024, then advanced by 1.23% to 0.36 in 2025, then gained by 11.08% to 0.4 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.4, 0.36, and 0.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	ADC Therapeutics	148.95 Mn	-70.15 Mn	17.14 Mn	0.42

Download Data